A. A. Hayes and S. Mooney, Feline mammary tumors, Vet Clin North Am Small Anim Pract, vol.15, pp.513-520, 1985.

W. Misdorp and K. Weijer, Animal model of human disease: breast cancer, Am J Pathol, vol.98, pp.573-576, 1980.

M. Castagnaro, C. Casalone, and E. Bozzetta, Tumour grading and the one-year post-surgical prognosis in feline mammary carcinomas, J Comp Pathol, vol.119, issue.3, pp.263-275, 1998.

M. Castagnaro, C. Casalone, and G. Ru, Argyrophilic nucleolar organiser regions (AgNORs) count as indicator of post-surgical prognosis in feline mammary carcinomas, Res Vet Sci, vol.64, issue.2, pp.97-100, 1998.

M. Castagnaro, D. Maria, R. Bozzetta, and E. , Ki-67 index as indicator of the post-surgical prognosis in feline mammary carcinomas, Res Vet Sci, vol.65, issue.3, pp.223-226, 1998.

T. Ito, T. Kadosawa, and M. Mochizuki, Prognosis of malignant mammary tumor in 53 cats, J Vet Med Sci, vol.58, issue.8, pp.723-726, 1996.

F. Millanta, M. Calandrella, and S. Citi, Overexpression of HER-2 in feline invasive mammary carcinomas: an immunohistochemical survey and evaluation of its prognostic potential, Vet Pathol, vol.42, issue.1, pp.30-34, 2005.

F. Seixas, C. Palmeira, and M. A. Pires, Grade is an independent prognostic factor for feline mammary carcinomas: a clinicopathological and survival analysis, Vet J, vol.187, issue.1, pp.65-71, 2011.

F. Gimenez, S. Hecht, and L. E. Craig, Early detection, aggressive therapy: optimizing the management of feline mammary masses, J Feline Med Surg, vol.12, issue.3, pp.214-224, 2010.

B. Brunetti, P. Asproni, and G. Beha, Molecular phenotype in mammary tumours of queens: correlation between primary tumour and lymph node metastasis, J Comp Pathol, vol.148, issue.2-3, pp.206-213, 2013.

G. P. Burrai, S. I. Mohammed, and M. A. Miller, Spontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor-and progesterone receptornegative breast lesions, BMC Cancer, vol.10, p.156, 2010.

D. Caliari, V. Zappulli, and R. Rasotto, Triple-negative vimentin-positive heterogeneous feline mammary carcinomas as a potential comparative model for breast cancer, BMC Vet Res, vol.10, p.185, 2014.

R. De-maria, M. Olivero, and S. Iussich, Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer, Cancer Res, vol.65, issue.3, pp.907-912, 2005.

F. Millanta, M. Calandrella, and I. Vannozzi, Steroid hormone receptors in normal, dysplastic and neoplastic feline mammary tissues and their prognostic significance, Vet Rec, vol.158, issue.24, pp.821-824, 2006.

R. Rasotto, D. Caliari, and M. Castagnaro, An immunohistochemical study of HER-2 expression in feline mammary tumours, J Comp Pathol, vol.144, issue.2-3, pp.170-179, 2011.

M. Soares, J. Correia, and P. Rodrigues, Feline HER2 protein expression levels and gene status in feline mammary carcinoma: optimization of immunohistochemistry (IHC)

, Microsc Microanal, vol.19, issue.4, pp.876-882, 2013.

D. A. Wiese, T. Thaiwong, and V. Yuzbasiyan-gurkan, Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype, BMC Cancer, vol.13, p.403, 2013.

M. D. Burstein, A. Tsimelzon, and G. M. Poage, Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer, Clin Cancer Res, vol.21, issue.7, pp.1688-1698, 2015.

P. Je´ze´quel, D. Loussouarn, and C. Guerin-charbonnel, Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response, Breast Cancer Res, vol.17, p.43, 2015.

P. Je´ze´quel, O. Kerdraon, and H. Hondermarck, Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications, Breast Cancer Res, vol.21, issue.1, p.65, 2019.

B. D. Lehmann, J. A. Bauer, and X. Chen, Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies, J Clin Invest, vol.121, issue.7, pp.2750-2767, 2011.

B. D. Lehmann, B. Jovanovic, and X. Chen, Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection, PLoS ONE, vol.11, issue.6, p.157368, 2016.

R. J. Dipaolo, D. D. Glass, and K. E. Bijwaard, CD4+CD25+ T cells prevent the development of organspecific autoimmune disease by inhibiting the differentiation of autoreactive effector T cells, J Immunol, vol.175, issue.11, pp.7135-7142, 2005.

J. Sz and A. Rudensky, Control of regulatory T cell lineage commitment and maintenance, Immunity, vol.30, issue.5, pp.616-625, 2009.

I. Kryczek, R. Liu, and G. Wang, FoxP3 defines regulatory T cells in human tumor and autoimmune disease, Cancer Res, vol.69, issue.9, pp.3995-4000, 2009.

S. D. Bohling and K. H. Allison, Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target, Mod Pathol, vol.21, issue.12, pp.1527-1532, 2008.

N. Maeda, K. Yoshimura, and S. Yamamoto, Expression of B7-H3, a potential factor of tumor immune evasion in combination with the number of regulatory T cells, affects against recurrence-free survival in breast cancer patients, Ann Surg Oncol, vol.21, pp.546-554, 2014.

J. Shou, Z. Zhang, and Y. Lai, Worse outcome in breast cancer with higher tumor-infiltrating FoxP3+ Tregs: a systematic review and meta-analysis, BMC Cancer, vol.16, p.687, 2016.

Y. Xu, L. S. Zheng, and Q. , Prognostic significance of infiltrating immune cell subtypes in invasive ductal carcinoma of the breast, Tumori, vol.104, issue.3, pp.196-201, 2018.

M. Yan, J. N. Byrne, and D. , Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers, Breast Cancer Res, vol.13, issue.2, p.47, 2011.

J. D. Fontenot, M. A. Gavin, and A. Y. Rudensky, FoxP3 programs the development and function of CD4+CD25+ regulatory T cells, Nat Immunol, vol.4, pp.330-336, 2003.

S. Hori, T. Nomura, and S. Sakaguchi, Control of regulatory T cell development by the transcription factor FoxP3, Science, vol.299, pp.1057-1061, 2003.

R. Khattri, T. Cox, and S. A. Yasayko, An essential role for Scurfin in CD4+CD25+T regulatory cells, Nat Immunol, vol.4, pp.337-342, 2003.

S. Lankford, C. Petty, and A. Lavoy, Cloning of feline FoxP3 and detection of expression in CD4+CD25+ regulatory T cells, Vet Immunol Immunopathol, vol.122, issue.1-2, pp.159-166, 2008.

C. S. Petty, M. B. Tompkins, and W. A. Tompkins, Transforming growth factor-beta/transforming growth factor-betaRII signaling may regulate CD4+CD25+ T-regulatory cell homeostasis and suppressor function in feline AIDS lentivirus infection, J Acquir Immune Defic Syndr, vol.47, issue.2, pp.148-160, 2008.

E. Dagher, J. Abadie, and D. Loussouarn, Bcl-2 expression and prognostic significance in feline invasive mammary carcinomas: a retrospective observational study, BMC Vet Res, vol.15, issue.1, p.25, 2019.
URL : https://hal.archives-ouvertes.fr/inserm-01991065

J. Morris, Mammary tumors in the cat: size matters, so early intervention saves lives, J Feline Med Surg, vol.15, pp.391-400, 2013.

L. N. Owen, TNM classification of tumours in domestic animals, 1980.

C. W. Elston and E. Io, Pathological prognostic factors in breast cancer: I-the value of histological grade in breast cancer: experience from a large study with longterm follow-up (Republished from Elston CW and Ellis IO, Histopathology, vol.19, pp.151-153, 1991.

E. Dagher, J. Abadie, and D. Loussouarn, Feline invasive mammary carcinomas: prognostic value of histological grading, Vet Pathol, vol.56, issue.5, pp.660-670, 2019.
URL : https://hal.archives-ouvertes.fr/inserm-02167919

T. Moriya, N. Kanomata, and Y. Kozuka, Usefulness of immunohistochemistry for differential diagnosis between benign and malignant breast lesions, Breast Cancer, vol.16, issue.3, pp.173-178, 2009.

M. M. Shamloula, S. H. El-shorbagy, and E. M. Saied, P63 and cytokeratin8/18 expression in breast, atypical ductal hyperplasia, ductal carcinoma in situ and invasive duct carcinoma, J Egypt Natl Canc Inst, vol.19, issue.3, pp.202-210, 2007.

A. Gama, A. Alves, and F. Schmitt, Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classification, Virchows Arch, vol.453, issue.2, pp.123-132, 2008.

S. Guil-luna, R. Sanchez-cespedes, and Y. Millan, Aglepristone decreases proliferation in progesterone receptorpositive canine mammary carcinomas, J Vet Intern Med, vol.25, issue.3, pp.518-523, 2011.

F. Nguyen, L. Pen?a, and C. Ibisch, Canine invasive mammary carcinomas as models of human breast cancerpart 1: natural history and prognostic factors, Breast Cancer Res Treat, vol.167, pp.635-648, 2018.

M. Yi, L. Huo, and K. B. Koenig, Which threshold for ER positivity? A retrospective study based on 9639 patients, Ann Oncol, vol.25, issue.5, pp.1004-1011, 2014.

M. Ono, H. Tsuda, and M. Yunokawa, Prognostic impact of Ki-67 labeling indices with 3 different cutoff values, histological grade, and nuclear grade in hormone-receptor-positive, HER2-negative, node-negative invasive breast cancers, Breast Cancer, vol.22, issue.2, pp.141-152, 2015.

A. C. Wolff, M. E. Hammond, and D. G. Hicks, Recommendations for human epidermal growth factor receptor 2 testing in breast cancer, J Clin Oncol, vol.31, pp.3997-4013, 2013.

M. Soares, J. Correia, and M. C. Peleteiro, St Gallen molecular subtypes in feline mammary carcinoma and paired metastases-disease progression and clinical implications from a 3-year follow-up study, Tumour Biol, vol.37, issue.3, pp.4053-4064, 2016.

S. Liu, W. D. Foulkes, and S. Leung, Prognostic significance of FoxP3+tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration, Breast Cancer Res, vol.16, issue.5, p.432, 2014.

S. Sun, X. Fei, and Y. Mao, PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients, Cancer Immunol Immunother, vol.63, issue.4, pp.395-406, 2014.

N. Oda, K. Shimazu, and Y. Naoi, Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients, Breast Cancer Res Treat, vol.136, issue.1, pp.107-116, 2012.

F. Liu, R. Lang, and J. Zhao, CD8 + cytotoxic T cell and FoxP3 + regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes, Breast Cancer Res Treat, vol.130, issue.2, pp.645-655, 2011.

S. Kim, A. Lee, and W. Lim, Zonal difference and prognostic significance of FoxP3 regulatory T cell infiltration in breast cancer, J Breast Cancer, vol.17, issue.1, pp.8-17, 2014.

G. J. Bates, S. B. Fox, and C. Han, Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse, J Clin Oncol, vol.24, issue.34, pp.5373-5380, 2006.

M. Gobert, I. Treilleux, and N. Bendriss-vermare, Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome, Cancer Res, vol.69, issue.5, pp.2000-2009, 2009.

A. N. Seo, H. J. Lee, and E. J. Kim, Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer, Br J Cancer, vol.109, issue.10, pp.2705-2713, 2013.

M. Takenaka, N. Seki, and U. Toh, FoxP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis, Mol Clin Oncol, vol.1, issue.4, pp.625-632, 2013.

K. Weijer and A. A. Hart, Prognostic factors in feline mammary carcinoma, J Natl Cancer Inst, vol.70, issue.4, pp.709-716, 1983.

M. S. Block and S. N. Markovic, The tumor/immune interface: clinical evidence of cancer immunosurveillance, immunoediting and immunosubversion, Am J Immunol, vol.5, pp.29-40, 2009.

G. P. Dunn, L. J. Old, and R. D. Schreiber, The immunobiology of cancer immunosurveillance and immunoediting, Immunity, vol.21, issue.2, pp.137-148, 2004.

G. P. Dunn, L. J. Old, and R. D. Schreiber, The three Es of cancer immunoediting, Annu Rev Immunol, vol.22, pp.329-360, 2004.

F. Qian, Y. Qingping, and W. Linquan, High tumorinfiltrating FoxP3+ T cells predict poor survival in estrogen receptor-positive breast cancer: a meta-analysis, Eur J Surg Oncol, vol.43, issue.7, pp.1258-1264, 2017.

N. R. West, S. E. Kost, and S. D. Martin, Tumour-infiltrating FoxP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer, Br J Cancer, vol.108, issue.1, pp.155-162, 2013.

S. Lee, E. Y. Cho, and Y. H. Park, Prognostic impact of FoxP3 expression in triple-negative breast cancer, Acta Oncol, vol.52, issue.1, pp.73-81, 2013.

E. M. De-kruijf, J. G. Van-nes, and A. Sajet, The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer, Clin Cancer Res, vol.16, issue.4, pp.1272-1280, 2010.

H. J. Lee, J. Y. Seo, and J. H. Ahn, Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients, J Breast Cancer, vol.16, issue.1, pp.32-39, 2013.

K. Baker, J. Lachapelle, and I. Zlobec, Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade, Histopathology, vol.58, issue.7, pp.1107-1116, 2011.

S. M. Mahmoud, E. C. Paish, and D. G. Powe, Tumour-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer, J Clin Oncol, vol.29, pp.1949-1955, 2011.

N. R. West, K. Milne, and P. T. Truong, Tumour-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in oestrogen receptor-negative breast cancer, Breast Cancer Res, vol.13, p.126, 2011.